Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note released on Tuesday,Benzinga reports. They currently have a $570.00 price target on the biopharmaceutical company’s stock.

Several other brokerages have also recently issued reports on ALNY. UBS Group boosted their price objective on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a research note on Friday, August 1st. JPMorgan Chase & Co. boosted their price objective on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an “overweight” rating in a research note on Wednesday, August 6th. Bank of America boosted their price objective on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a “buy” rating in a research note on Friday, July 11th. Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Finally, Truist Financial began coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, July 21st. They set a “buy” rating and a $385.00 price target for the company. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $412.79.

Alnylam Pharmaceuticals Trading Up 0.1%

Shares of ALNY opened at $447.00 on Tuesday. Alnylam Pharmaceuticals has a fifty-two week low of $205.87 and a fifty-two week high of $469.81. The stock has a fifty day moving average of $379.67 and a two-hundred day moving average of $305.57. The company has a market capitalization of $58.59 billion, a PE ratio of -180.97 and a beta of 0.32. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $773.69 million during the quarter, compared to analysts’ expectations of $633.54 million. During the same period in the previous year, the company earned ($0.13) EPS. The business’s quarterly revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 1,455 shares of the business’s stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total value of $666,986.55. Following the transaction, the executive vice president owned 20,221 shares in the company, valued at $9,269,508.61. The trade was a 6.71% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Dennis A. Ausiello sold 31,448 shares of the business’s stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director owned 911 shares in the company, valued at $397,724.38. This represents a 97.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 57,594 shares of company stock worth $25,551,456 over the last three months. Insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock valued at $4,336,064,000 after purchasing an additional 240,534 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 0.8% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock valued at $1,192,988,000 after purchasing an additional 33,696 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Alnylam Pharmaceuticals by 5.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock valued at $946,466,000 after purchasing an additional 185,783 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 3.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock valued at $779,857,000 after purchasing an additional 75,936 shares in the last quarter. Finally, Orbis Allan Gray Ltd raised its stake in shares of Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after purchasing an additional 486,489 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.